JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.58 CNY | -6.00% |
|
-7.45% | -26.15% |
| Mar. 07 | Jian Yisheng Pharma Sets Up 3 Million Yuan Subsidiary | MT |
| 2023 | Jilin Jian Yisheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2021 | 878M 121M | Sales 2022 | 830M 115M | Capitalization | 2.68B 370M |
|---|---|---|---|---|---|
| Net income 2021 | 96M 13.26M | Net income 2022 | 83M 11.47M | EV / Sales 2021 | 3.52 x |
| Net Debt 2021 | 95.24M 13.16M | Net Debt 2022 | 40.44M 5.59M | EV / Sales 2022 | 3.28 x |
| P/E ratio 2021 |
31.2
x | P/E ratio 2022 |
32.3
x | Employees | 1,764 |
| Yield 2021 |
0.33% | Yield 2022 |
0.62% | Free-Float | 52.64% |
More Fundamentals
* Assessed data
More news
| 1 day | -6.00% | ||
| 1 week | -7.45% | ||
| Current month | -8.74% | ||
| 1 month | -6.67% | ||
| 3 months | -26.07% | ||
| 6 months | -26.89% | ||
| Current year | -26.15% |
1 week
6.46
7.30
1 month
6.467.75
Current year
5.209.58
1 year
5.2010.21
3 years
5.2012.34
5 years
5.2012.34
10 years
5.2026.87
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Min Xie
CEO | Chief Executive Officer | 66 | 08-12-31 |
Jian Tao Bi
DFI | Director of Finance/CFO | 54 | 11-07-31 |
Tie Jun Li
PSD | President | 64 | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Rong Sun
BRD | Director/Board Member | 68 | 22-05-10 |
Yi Sheng Zhang
CHM | Chairman | 68 | 99-12-31 |
Xiao Min Xie
CEO | Chief Executive Officer | 66 | 08-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 6.58 | -6.00% | 8,038,028 |
| 24-04-12 | 7 | -0.99% | 4,141,227 |
| 24-04-11 | 7.07 | -0.42% | 4,384,000 |
| 24-04-10 | 7.1 | -3.27% | 5,959,700 |
| 24-04-09 | 7.34 | +3.23% | 5,868,927 |
End-of-day quote Shenzhen S.E., April 14, 2024
More quotes
JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and distribution of Chinese patent drugs for the treatment of cardiovascular and cerebrovascular disease. The Company's main products consist of Shengmai injections, Zhenyuan capsules, Xinyue capsules, Qingkailing injections and Guifu Dihuang capsules, among others. The Company's products are applied in the treatment for heart cerebrovascular diseases and detoxification. The company also provides health care products and cosmetics. The Company distributes its products within China market.
Sector
Pharmaceuticals
Calendar
2024-04-18
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -26.15% | 320M | |
| +28.79% | 677B | |
| +25.94% | 560B | |
| -5.84% | 355B | |
| +15.75% | 319B | |
| +4.32% | 287B | |
| +4.00% | 214B | |
| +1.92% | 207B | |
| -7.93% | 199B | |
| -10.00% | 146B |
- Stock Market
- Equities
- 002566 Stock
